NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/31/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization61.01 mln
Float12.94 mln
Earnings Date08/18/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
23.00
Transformational upside
Relative Strength
90
/ 100
Top performer
Debt / Equity
0.39
Low leverage
ROE
-382
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Cingulate Inc. is a US-based pharmaceutical company focused on developing new treatments for ADHD and anxiety disorders. Its most advanced drug, CTx-1301, is currently in Phase 3 clinical trials for ADHD patients across all age groups, while CTx-2103 is being developed to treat anxiety and CTx-1302 is planned for future clinical testing as an additional ADHD therapy. Founded in 2012 and based in Kansas City, Kansas, the company uses its proprietary drug delivery technology as the foundation for all its products.
